Skip to content

Brain Health Nexus

Founding Steering Committee

The Brain Health Nexus Founding Steering Committee (FSC) is composed of international leaders in the brain health ecosystem who have directly participated in and/or led previous roadmapping efforts; embrace the one system vision of working across diseases, disciplines and other silos; and are committed to driving a shared mission and collective action.

The main purpose of the FSC is to establish a framework for developing an actionable roadmapping strategic and operational plan, based on collective experience. This framework will be communicated via a Draft White Paper to the participants of the Summit for input and consensus.

Executive Leaders

Executive Leaders
Co-Chair
Magali Haas, MD, PhD
Magali Haas, MD, PhD

CEO & President
Cohen Veterans Bioscience

Nicole Harmon, PhD
Nicole Harmon, PhD

Executive Director, External Affairs
Cohen Veterans Bioscience

bhn-inez-jabalpurwala
Inez Jabalpurwala, MBA

Global Director
Viral Neuro Exploration (VINEx)

Members

Harris Eyre, MD, PhD
Harris A. Eyre, MD, PhD

Co-founder
PRODEO Institute

Brad Herbert, MBA
Brad Herbert, MBA

CEO
Healthy Brains Global Initiative

bhn-sean-hill
Sean Hill, PhD

Inaugural Director
Krembil Centre for Neuroinformatics at CAMH

Peter Hoehn
Peter Hoehn

Head, Commercial Strategy 
Johnson & Johnson Science for Minds

Wolfgang H. Oertel, MD
Wolfgang H. Oertel, MD

Hertie Senior Research Professor
Hertie Foundation at the Philipps Universität Marburg

Shekhar Saxena, MD
Shekhar Saxena, MD

Professor of the Practice of Global Mental Health
Harvard T. H. Chan School of Public Health

Strategic Plan Inputs & Outputs

The Steering Committee will work on multiple workstreams that will inform the development of a strategic plan for building a roadmap of achievable, cross-sector impacts in the brain health ecosystem for the next five years.

Survey

Surface Brain Health Nexus summit expectations, insights on collaboration opportunities, field challenges, and common priorities

Interviews

Gain deeper insight into the motivations, goals and priorities of the brain health field and other feedback for fostering the buy-in and long-term engagement

White Paper

Underscore the rationale and urgent need for a shift from symptom-based, clinically empirical approaches to mechanism-based, data-driven approaches in the brain health ecosystem

Roles/Responsibilities

The full Steering Committee will be recruited in February/March 2022 and in place by April 1, 2021.

Pre-Summit:

  • Provide survey & interview protocol feedback
  • BHN steering committee meeting participation
  • White Paper development

Post-Summit:

  • Leadership of Working Groups to further expand pillars
  • Leverage networks to assist with outreach and execution of the Roadmap
  • Support of ongoing dialogue with brain initiative leaders globally
  • Serve as ambassadors of the Brain Health Nexus
  • Act as a conduit in information sharing in the brain health ecosystem
Share Your Thoughts - Take the Nexus Survey

We need your voice to help shape the future of this effort and make effective change. 

We invite you to join our network of advocates and lend your expertise to this coordinated action in response to this global public health crisis.

Please watch this webinar to learn more about our goals and the scope of this effort, and most important, please complete the survey.

We want your perspective and expertise on current barriers, prioritized gaps, and a possible course of action. The survey will feed into a white paper that will build toward a roadmap designed for collaborative engagement.

Magali Haas, MD, PhD

CEO & President
Cohen Veterans Bioscience

Dr. Haas is Chair, CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in New York City whose mission is to fast-track diagnostics and therapeutics to advance precision brain health. Magali has over 15 years of pharmaceutical executive experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in early and late stage neuroscience clinical development, translational medicine, diagnostics and integrative solutions. To pioneer new approaches for precision therapeutics for brain health, she founded Orion Bionetworks in 2012, which was transformed to Cohen Veterans Bioscience in 2015, while also serving as founding Chief Science and Technology Officer for One Mind for Research. She serves on several advisory boards including Alto Neurosciences, Partnership for Assessment and Accreditation of Scientific Practice, VirtualBrainCloud, Krembil Centre for Neuroinformatics and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience with distinction from Albert Einstein College of Medicine.

Nicole Harmon, PhD

Executive Director, External Affairs
Cohen Veterans Bioscience

Dr. Nicole Harmon is a PhD-trained therapist with over 20 years of experience in psychology, philanthropy, patient advocacy, public health, and clinical research. She is currently the Executive Director of External Affairs at Cohen Veterans Bioscience (CVB), a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.. 

At CVB, Dr. Harmon leads the organization’s communication campaigns and strategic partnership development with Veterans service and other disease-focused patient advocacy organizations to further CVB’s collaborative efforts to bring solutions to brain health challenges. She has collaborated with CVB leaders to establish the Brain Trauma Blueprint, a multi-stakeholder roadmapping effort facilitated through State of the Science Summits aimed at galvanizing leaders across the government, industry, academic, and not-for-profit sectors and accelerating an era of personalized medicine for traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD).

Prior to joining CVB, Dr. Harmon served as a leader for several non-profit organizations focused on health advocacy and improving research standards and care. Her most recent role as Chief Operating Officer for Clinical Data Interchange Standards Consortium (CDISC), a global consensus based standards development organization and the FDA’s partner for data standards, provided her the opportunity to speak internationally on the need for data to “speak the same language,” spearheading global data sharing and harmonization initiatives to reduce silos and positively impact clinical research.   During her tenure there she transformed CDISC’s financial roadmaps, program management and global brand. Additionally, she developed and managed complex partnerships with leading U.S and International funding partners, U.S. FDA, Japan PMDA, European Medicines Agency, NIH, WHO, EU’s Innovative Medicines Initiatives, Global Patient Foundations successfully achieving funding for and administering multiple large-scale projects.  Prior to her time with CDISC, Dr. Harmon evaluated patients with Traumatic Brain Injury and Psychiatric conditions in a post-acute rehabilitation hospital.

Nicole earned her doctorate in Counselor Education and Supervision where her research focused on the “Long Term Needs of Caregivers Following Acquired Brain Injury.” This research led to many opportunities to speak nationally and internationally, as well as to lead consortia to advocate for collaboration among the research and rehabilitation community to recognize brain injury as a chronic disease. 

Inez Jabalpurwala, MBA

Global Director
Viral Neuro Exploration (VINEx)

Inez has extensive experience leading cross-sector collaborations with organizations in health research, academia, and international development. She is currently Global Director of VINEx, a non-profit corporation initiated by the private medical device company, Rocket Science Health, to understand how viruses and other global environmental phenomena may affect the central nervous system. She was the Founding President and CEO of the Brain Canada Foundation from 2001 to 2020. When she joined, the organization had about $1 million in assets; she grew this to over $300 million. Under her leadership Brain Canada provided research grants totaling $250 million and involving more than 1,000 scientists and clinicians based at 115 institutions across Canada. To achieve these results, Inez managed multiple stakeholders, and secured more than 100 partnerships, including leading the approach to secure $160 million in matching funds from the Government of Canada, and fundraising to secure $130 million from a range of donors, institutions and organizations.

Inez has previously been a member of the US National Institutes of Health BRAIN Initiative Multi-Council Working Group; the Institute of Medicine (of the National Academies) Forum on Neuroscience and Nervous System Disorders; and BrainsCAN, a $66-million investment by the Government of Canada based at the University of Western Ontario, which seeks to create synergies with other Canadian institutions and international partners in the private and public sectors. She currently serves on the Board of Equitas—International Centre for Human Rights Education; is the immediate past President of the McGill Alumni Association, and on the Board of Governors of McGill University; a Desautels Global Expert in McGill University’s Faculty of Management; and a mentor through the Loran Scholars Program.

Inez is a member of the Economic Development and Public Finance committee of the Board of Trade of Metropolitan Montreal; a member of the Association of Quebec Women in Finance; a member of the International Women’s Forum; and a member of the Women’s Brain Health Initiative. She is passionate about equity, diversity and inclusion in science and in society.

Inez was named one of Canada’s Most Powerful Women: Top 100 by the Women’s Executive Network, in the “Trailblazers and Trendsetters Category” in 2007 and again in 2016. A skilled public speaker, she has been featured at major conferences around the world.

Inez holds a BA and MA in English Literature, and an MBA from McGill University; she has also completed the Master of Management program for voluntary sector leaders. Inez resides in Montreal, Quebec.

Harris A. Eyre, MD, PhD

Co-founder
PRODEO Institute

Dr. Eyre is an executive working to optimize brain function in the modern world. He is co-lead of the OECD-PRODEO Institute Neuroscience-inspired Policy Initiative, which seeks to advance brain-based policy and investment innovations. He is President of PRODEO a group of streetwise and mission-driven brain health executives. He maintains advisory or adjunct roles with the Healthy Brains Global Initiative, Baylor College of Medicine, BrainLat, the American Psychological Association, the American Association of Geriatric Psychiatry, Deakin University, the University of Melbourne and The University of Adelaide.

Dr. Eyre has authored 100+ papers and chapters in outlets such as Lancet Neurology, Neuron, World Psychiatry and The RSA Journal. He co-edited the book ‘Convergence Mental Health’ (Oxford University Press).

Brad Herbert, MBA

CEO
Healthy Brains Global Initiative

Brad Herbert has more than 40 years of experience in international development with a focus in the social sectors, including health and education. Brad worked with the World Bank for 29 years and spent the majority of his tenure based in developing countries, learning firsthand the value of country-led partnerships.  

In 2002, he left the World Bank to help establish the Global Fund to Fight HIV/AIDs, TB and Malaria. At the Global Fund, Brad was the Chief of Operations, with the rank of Assistant Secretary General at the World Health Organization. While at the Global Fund, he was directly responsible for putting in place the operational policies and the management team responsible for delivering the Global Fund’s multi-billion-dollar grant program in over 130 countries.  Brad has also spent many years serving on and chairing boards for international not-for-profit organizations.  He chaired the board of Mothers 2 Mothers, a not-for-profit organization based in Cape Town and in 2017 was asked by the new Deputy Secretary General of the UN to take over as Co-Chair of the Water Supply and Sanitation Collaborative Council, a UN organization based in Geneva. 

Brad has managed major changes in management processes and helped to restructure several organizations. As a result of these years of development experience, his leadership roles, and his practical results-oriented approach to program policy, development, and accelerated program implementation, Brad was asked to take on the role of the first CEO of the Healthy Brains Global Initiative (HBGI).  

Sean Hill, PhD

Inaugural Director
Krembil Centre for Neuroinformatics at CAMH

Dr. Sean Hill is the Inaugural Director of the Krembil Centre for Neuroinformatics, at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada and Professor in the Departments of Psychiatry and Physiology at the University of Toronto. He is also Titular Professor at the École polytechnique fédérale de Lausanne, Switzerland. Under Dr. Hill’s leadership, the Krembil Centre for Neuroinformatics applies state-of-the-art data science, artificial intelligence, and multi-scale computational modeling to accelerate the diagnosis, prediction and treatment of brain disorders. After completing his Ph.D. in computational neuroscience at the Université de Lausanne, Dr. Hill held postdoctoral positions at The Neurosciences Institute in La Jolla, California and the University of Wisconsin, Madison. He then joined the Computational Biology group at IBM Research.

Dr. Hill has served as a co-director of the Blue Brain Project, leading the Neuroinformatics division. He led the Neuroinformatics strategy and platform development in the Human Brain Project (2013-2016). He served as Executive Director (2011-2013) and Scientific Director (2014-2016) of the International Neuroinformatics Coordinating Facility at the Karolinska Institutet in Stockholm, Sweden.

Dr. Hill has extensive experience in large-scale data integration, and building and simulating biophysically-detailed models of brain circuitry. His research focuses on the cellular basis of brain states within thalamocortical circuitry. He has developed numerous large-scale models of cortical and corticothalamic systems during wakefulness, sleep and anesthetic conditions, which have contributed to our understanding of the cellular and synaptic mechanisms underlying diverse brain states.  

Peter Hoehn

Head, Commercial Strategy
Johnson & Johnson Science for Minds

Peter Hoehn is currently Head, Commercial Strategy for Johnson & Johnson Science for Minds, focusing on innovative digital solutions and data for Serious Mental Illness and dementia.  In this role Peter is responsible for developing the overarching global strategy, portfolio recommendations, investment approach, external collaborations, and business models to establish new value creating digital business ventures.

Previously, Peter Hoehn was the Co Dx, Commercial Strategy Leader within the Global Commercial Strategy Organization of Janssen Pharmaceuticals, responsible for leading strategic marketing and market access for companion and complementary diagnostics (Co Dx) across all Therapeutic Areas.  Peter and his team lead the assessment of potential diagnostic projects and commercial evaluation of prospective diagnostic partners, and lead commercial strategy development, market access strategy and launch readiness for Janssen Co Dx projects.

Peter joined Johnson & Johnson in 2003 in the Pharmaceuticals Group Strategic Marketing organization as Global Commercial Leader for Reminyl, and in 2005 was promoted to Global Marketing Leader – Neurology, where he had global commercial responsibility for in-line neurology products as well as products in late stage of development.  In 2008 Peter joined the Ortho Clinical Diagnostics (OCD) organization as Global Marketing Leader and was promoted to Vice President for WW Marketing and Strategic Marketing in 2010, and continued in this role at OCD until moving back to the Janssen Pharmaceuticals Business as Co Dx Commercial Strategy Leader. 

Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University.  He started his career as a corporate lawyer, and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer at BMS, Peter moved into various strategy, marketing and sales management roles.

Wolfgang H. Oertel, MD

Hertie-Senior-Research Professor
Hertie Foundation at the Philipps Universität Marburg

Prof. Oertel is Hertie-Senior-Research-Professor (2014- 2022), Professor for Neurology and former Chairman (1996-2014) at the Dept. Neurology, Philipps University Marburg, Germany. Prof. Oertel has served as president (2007-2011) of the German Parkinson Society (DPG), as board member (2009-2014) and president (2011-2012) of the German Society for Neurology, treasurer (2001-2002) of the International Movement Disorder Society (MDS), chairperson (2007-2009) of the European section of MDS and president (2013-2015) of the International REM-Sleep Behaviour Disorder Study Group, an organization he founded in 2009. In respect to infrastructural achievements he founded the German Brain Bank System in 1994, the German Competence Network Parkinson in 1999 – which he still coordinates – and initiated the Hertie Institute of Clinical Neuroscience, Tübingen, Germany (2000). 

From 2015-2020 he was member and the representative of the European Academy of Neurology (EAN) in the high level advisory group “Scientific Panel for Health (SPH)” to the European Commissioner for “Research and Innovation”. Since 2018 he is the Vice-President of the European Brain Council, Brussels. 

Prof. Oertel’s main field of scientific interest are the prodromal and manifest stages of neurodegenerative disorders such as Alzheimer dementia and Parkinson’s disease and related disorders. In parallel he also keeps a strong interest in Restless Legs Syndrome. He has published over 800 reviewed scientific articles (h-factor: >110).

Shekhar Saxena, MD

Professor of the Practice of Global Mental Health
Harvard T. H. Chan School of Public Health

Shekhar Saxena is Professor of the Practice of Global Mental Health at the Department of Global Health and Population at the Harvard T. H. Chan School of Public Health. A psychiatrist by training, he was in the faculty of AIIMS, New Delhi before he joined World Health Organization (WHO) in 1998. From 2010 to 2018 he was the Director of the Department of Mental Health and Substance Abuse at WHO. Author of more than 300 academic papers, he was an editor of the Lancet Commission on Global Mental Health and Sustainable Development 2018.

His expertise includes providing evidence-based advice and technical assistance to policy makers, businesses and civil society on mental health promotion and prevention and management of mental, developmental, neurological and substance use disorders and suicide prevention.